Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E–Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study

PURPOSE: To determine the safety and preliminary efficacy of selective combination targeted therapy for BRAF V600E–mutant metastatic colorectal cancer (mCRC) in the safety lead-in phase of the open-label, randomized, three-arm, phase III BEACON Colorectal Cancer trial (ClinicalTrials.gov identifier:...

Full description

Saved in:
Bibliographic Details
Published in:J Clin Oncol
Main Authors: Van Cutsem, Eric, Huijberts, Sanne, Grothey, Axel, Yaeger, Rona, Cuyle, Pieter-Jan, Elez, Elena, Fakih, Marwan, Montagut, Clara, Peeters, Marc, Yoshino, Takayuki, Wasan, Harpreet, Desai, Jayesh, Ciardiello, Fortunato, Gollerkeri, Ashwin, Christy-Bittel, Janna, Maharry, Kati, Sandor, Victor, Schellens, Jan H.M., Kopetz, Scott, Tabernero, Josep
Format: Artigo
Language:Inglês
Published: American Society of Clinical Oncology 2019
Subjects:
RAPID COMMUNICATION
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7370699/
https://ncbi.nlm.nih.gov/pubmed/30892987
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.18.02459
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items